Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Oral Medicine Department, Sírio-Libanês Hospital, São Paulo, Brazil.
J Oral Pathol Med. 2018 Apr;47(4):417-424. doi: 10.1111/jop.12695. Epub 2018 Mar 3.
Fibroblast growth factor 2 (FGF2) and FGF receptor 1 (FGFR1) have been investigated in different human neoplasms and were shown to play important roles in the pathogenesis of these diseases; however, very few are known regarding their prognostic importance in the context of ameloblastoma. Therefore, the aim of this study was to investigate whether the expression of FGF2 and FGFR1 is associated with ameloblastoma clinical behavior.
Fifty-eight cases of ameloblastoma arranged in tissue microarray were submitted to immunohistochemistry against FGF2 and FGFR1. Clinicopathological parameters regarding sex, age, tumor size, duration and location, treatment, recurrences, radiographic features, cortical disruptions, and follow-up data were obtained from patients' medical records and correlated with the molecules expression. Univariate and multivariate Cox regression analyses were used to investigate the prognostic potential of the biomarkers.
Forty-four cases (75.9%) exhibited cytoplasmic positivity for FGF2 in central and peripheral epithelial cells, 46 of 58 (79.3%) showed FGFR1 cytoplasmic positivity predominantly in the columnar peripheral cells, and 43 cases (74.1%) were positive for both. Expression of FGF2 and FGF2 + FGFR1 was associated with tumor recurrences (P = .05). However, univariate and multivariate analyses did not demonstrate a significant influence of FGF2, FGFR1, or FGF2 + FGFR1 in the 5-year disease-free survival (DFS) rate (P = .27, P = .33, and P = .25, respectively).
Cytoplasmic expression of FGF2 and FGF2 + FGFR1 is associated with ameloblastoma recurrence, but FGF2 and FGFR1 are not determinants of a lower DFS.
成纤维细胞生长因子 2（FGF2）和 FGF 受体 1（FGFR1）已在不同的人类肿瘤中进行了研究，并被证明在这些疾病的发病机制中发挥着重要作用；然而，在成釉细胞瘤的背景下，关于其预后意义的了解甚少。因此，本研究旨在探讨 FGF2 和 FGFR1 的表达是否与成釉细胞瘤的临床行为有关。
将 58 例成釉细胞瘤组织微阵列进行免疫组织化学染色，以检测 FGF2 和 FGFR1 的表达。从患者的病历中获取性别、年龄、肿瘤大小、病程和部位、治疗、复发、影像学特征、骨皮质破坏和随访数据等临床病理参数，并与分子表达进行相关性分析。采用单因素和多因素 Cox 回归分析来探讨生物标志物的预后潜力。
44 例（75.9%）的中央和周围上皮细胞出现细胞质 FGF2 阳性，46 例（79.3%）的柱状周围细胞出现 FGFR1 细胞质阳性，43 例（74.1%）的 FGFR1 阳性。FGF2 和 FGF2+FGFR1 的表达与肿瘤复发相关（P=0.05）。然而，单因素和多因素分析均未显示 FGF2、FGFR1 或 FGF2+FGFR1 对 5 年无病生存率（DFS）有显著影响（P=0.27、P=0.33 和 P=0.25）。
细胞质 FGF2 和 FGF2+FGFR1 的表达与成釉细胞瘤的复发有关，但 FGF2 和 FGFR1 不是降低 DFS 的决定因素。
